Suchergebnisse - "Spiekermann, Karsten"

PubPharm (14)

1

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

enthalten in: Blood | 2023

von Roas, M. | Vick, B. | Kasper, M. | +21

2

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML

enthalten in: Scientific reports | 2021

von Kempf, J. | Weser, S. | Bartoschek, M. | +17

3

A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia

enthalten in: European journal of medicinal chemistry | 2020

von Sellmer, A. | Pilsl, B. | Beyer, M. | +13

4

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia

enthalten in: Leukemia | 2019

von Angenendt, L. | Bormann, E. | Pabst, C. | +31

5

Imatinib dose reduction in major molecular response of chronic myeloid leukemia : results from the German Chronic Myeloid Leukemia-Study IV

enthalten in: Haematologica | 2019

von Michel, C. | Burchert, A. | Hochhaus, A. | +58

CommentIn: Haematologica. 2019 May;104(5):862-864. - PMID 31040230

6

The target landscape of clinical kinase drugs

enthalten in: Science (New York, N.Y.) | 2017

von Klaeger, S. | Heinzlmeir, S. | Wilhelm, M. | +45

CommentIn: Br J Cancer. 2018 Apr;118(7):936-937. - PMID 29545596

7

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia

enthalten in: Nature medicine | 2017

von Göllner, S. | Oellerich, T. | Agrawal-Singh, S. | +25

8

Long-term follow-up of cytogenetically normal CEBPA-mutated AML

enthalten in: Journal of hematology & oncology | 2014

von Pastore, F. | Kling, D. | Hoster, E. | +10

9

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

enthalten in: Haematologica | 2014

von Hanfstein, B. | Lauseker, M. | Hehlmann, R. | +27

10

The NPM1 mutation type has no impact on survival in cytogenetically normal AML

enthalten in: PloS one | 2014

von Pastore, F. | Greif, P. | Schneider, S. | +12